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Glycosaminoglycans (GAGs) are complex polysaccharides
composed of hexosamine-containing disaccharide repeating
units. The three most studied classes of GAGs, heparin/
heparan sulfate, hyaluronan and chondroitin/dermatan
sulfate, are essential macromolecules. GAGs isolated from
animal and microbial sources have been utilized therapeut-
ically, but naturally occurring GAGs are extremely hetero-
geneous limiting further development of these agents.
These molecules pose difficult targets to construct by clas-
sical organic syntheses due to the long chain lengths and
complex patterns of modification by sulfation and epimeri-
zation. Chemoenzymatic synthesis, a process that employs
exquisite enzyme catalysts and various defined precursors
(e.g. uridine 5′-diphosphosphate-sugar donors, sulfate
donors, acceptors and oxazoline precursors), promises to
deliver homogeneous GAGs. This review covers both theor-
etical and practical issues of GAG oligosaccharide and
polysaccharide preparation as single molecular entities and
in library formats. Even at this early stage of technology
development, nearly monodisperse GAGs can be made
with either natural or artificial structures.
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Carbohydrates play many roles in biology, but the glycosami-
noglycans (GAGs) of animals are truly exceptional polymers
with a plethora of chemical structures and bioactivities
(Sugahara et al. 2003; Toole 2004; Bishop et al. 2007). The
three most abundant classes of GAG polymers in vertebrates
are (i) heparan sulfate (HS) and heparin, (ii) hyaluronan (HA)
and (iii) chondroitin sulfate (CS) and dermatan sulfate (DS).
HS is found throughout the animal kingdom including the
primitive coelenterates (e.g. Hydra); thus, it appears that the
most complicated GAG is also the most primordial
(DeAngelis 2002). Unsulfated chondroitin exists in nematodes
(e.g. Caenorhabditis), whereas poorly sulfated CS is found in
arthropods (e.g. Drosophila) and more extensively sulfated
CS in most animals. HA appears to be the most recent GAG
to evolve in animals and is only found in chordates (e.g.
Amphioxus and higher). Most, if not all, mammalian cells or
their surrounding extracellular matrix possesses at least one of
the types of the GAG molecule, but in many cases, multiple
GAGs co-exist. Genetic knockout or knockdown studies in
various organisms from worms to mice demonstrate that the
GAGs are crucial for development/organogenesis and thus
appear to be essential for multicellular life.
Natural GAG and glycoconjugate structures
The GAG chains of animals are polysaccharides composed of
repeating disaccharide building blocks constructed from a
hexosamine and an uronic acid residue (Table I). Keratan
sulfate (KS) is another member of the GAG family, but due
to its distinctive structure, lack of uronic acid, relatively low
abundance in the body and less well-known biological roles,
KS will not be covered in this review. In vertebrates, the back-
bones of HS and CS (heparosan and chondroitin, respectively)
are modified by sulfation, but HA is not sulfated naturally. In
more ancient animals, sulfation on chondroitin does not
always occur. In more evolutionarily modern organisms, some
of the HS and CS backbones are further modified by C5-epi,
resulting in the conversion of D-glucuronic acid (GlcA) to
L-iduronic acid (IdoA). It is well-known that the level of sulfa-
tion and epimerization varies from slight to extreme depend-
ing on the organism, tissue, developmental stage and health
status; this diversity as well as heterogeneity makes GAG ana-
lysis and synthesis challenging (Laremore et al. 2009).
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All three GAGs can be found attached to proteins during
their duty cycle in the body. For example, HA is initially bio-
synthesized without a protein-based primer or core, but in
some tissues and fluids, a fraction of the HA is covalently
attached to inter-α-trypsin inhibitor forming a HA–SHAP
complex and it gains a new function (Zhuo et al. 2006). In
contrast, both CS and HS are always built in the Golgi on a
tetrasaccharide linkage region attached to various secreted or
membrane-bound core proteins. Heparin, one of the most
widely used drugs in hospitals, is actually a heavily modified
form of HS that is released from its core protein and stored
intracellularly in mast cell granules (Linhardt 2003).
Due to the abundance of hydroxyl and carboxyl groups as
well as in many cases, sulfo groups, GAGs exhibit a hydro-
philic, cation-binding physiochemical nature. The resulting
hydrated and anionic GAG structure, especially in the case of
HA, is an important factor for creating various anatomical
structures including the eyes, joints, heart and myriad intricate
tissues. Probably more important are the biological interactions
of GAGs with various protein-based receptors, adhesions and
fibrous elements. In many cases, cell–cell or cell–matrix adhe-
sion in mammals relies on the GAGs. In addition to serving as
anchors, GAGs, especially HS and HA, have very important
roles in signaling. For example, GAG-stimulated pathways are
used to control cellular behavior including proliferation, differ-
entiation and motility.
Many different oligosaccharide sequences differing in
sulfate and IdoA content and distribution are present in the sul-
fated GAGs, giving them the potential to bind numerous
protein ligands and effectors in a selective manner. Organizing
and maintaining the trillions of human cells, present in 200
different cell types, GAGs could certainly make use of such
coding. The hypothesis that GAGs have a sulfate code that
might be deciphered is a topic of great interest (Bülow and
Hobert 2006; Kreuger et al. 2006; Ly et al. 2011; Li, Ly, et al.
2012). Understanding this “code” requires access to pure and
chemically defined GAGs or GAG fragments.
Experimental issues and caveats with natural GAG extracts
GAGs are often extracted from animal tissues or prepared
through microbial fermentation (Linhardt and Gunay 1999;
DeAngelis et al. 2002; Widner et al. 2005; Wang et al. 2010;
Bhaskar et al. 2012). Industries operate at the ton scale for
heparin (porcine intestine), HA (rooster comb; Streptococcus
or recombinant Bacillus bacteria) and CS (bovine or shark
cartilage) production (Bhaskar et al. 2012). GAG biosynthesis
in vivo results in a variety of sizes and modification patterns;
thus, there will also always be some variability in GAGs
obtained from natural sources. Furthermore, seasonal varia-
tions, environmental factors, feedstocks as well as the intrinsic
differences between animal breeds add to the variability of
naturally occurring GAGs. Typically, large-scale physico-
chemical separation technologies cannot resolve completely
intact GAGs; thus, most commercial preparations are quite
often heterogeneous with respect to size and/or sulfation. In
some cases, due to the similar nature of GAGs, cross-
contamination of HS and the various forms of CS and DS can
also occur. One expensive and generally effective method-
ology utilizes selective GAG degrading enzymes (e.g. heparin
lyases or chondroitin lyases) to remove the undesirable GAG
impurities from the target GAG. This approach, however, is
not useful for the large-scale (kilogram to ton) production of
pure GAGs. Another issue is that other potentially bioactive
entities (i.e. virus, prions or growth modulating factors) may
remain associated with the GAG chains in extracts; thus, ex-
tremely careful preparation and analysis is required for any
naturally derived extract including recombinant vertebrate
systems.
On the industrial scale, since a large population of animals
is required, the supply chain is immense and globally intercon-
nected and has been subject to willful contamination as seen in
the 2008 Chinese heparin crisis (Liu et al. 2009). Somewhere
in the heparin production process, presumably after the extrac-
tion of crude heparin from tissue at the slaughterhouse and
before the manufacture of the active pharmaceutical ingredient
(pharmacopeial heparin) using certified Good Manufacturing
Processes in a pharmaceutical company, the heparin was adult-
erated with a chemically modified oversulfated CS (Guerrini
et al. 2008). This contaminated heparin went undetected
because of limitations in the pharmacopeial assays used at the
time and entered the market place resulting in serious adverse
side effects associated with the death of over 100 patients. This
worldwide crisis has led to more stringent control of the manu-
facture and testing of heparin, but animal sourced GAGs will
always pose a risk because their naturally complex structure
makes assessing the presence of unknown contaminants diffi-
cult and because of the vastly different level of regulations for
the food chain and the drug chain.
To avoid these kinds of problems, there is a need to produce
GAGs synthetically. One early success story is Arixtra, a sul-
fated pentasaccharide that binds and activates antithrombin III
and is the active sequence in therapeutic heparin. However, the
synthesis of this relatively simple pentasaccharide required
dozens of chemical steps. The chemical synthesis of oligosac-
charides longer than five sugar units with selectivity and reason-
able yield is virtually impossible using conventional methods
based on orthogonal blocking groups and selective protection
and deprotection. In addition, chemical synthesis often results in
the undesired formation of toxic byproducts and waste solvents
that may contaminate the product and the environment.
Table I. Animal GAGs and their major backbone structures






DS [-4-IdoAα or GlcA2X β–1-3-GalNAc4X6X -β1-]n
Heparosan [-4-GlcAβ1-4-GlcNAc-α1-]n
HS [-4-GlcAβ or IdoA2Xα-1-4-GlcNY3X6X-α1-]n
Heparin [-4-IdoAα or GlcA2Xβ/-1-4-GlcNY3X6X-α1-]n
GlcA, glucuronic acid; IdoA, iduronic acid; GalNAc, N-acetylgalactosamine;
GlcNAc, N-acetylglucosamine; GlcN, glucosamine; Y = Ac, SO3
−, or H;
X = OH or SO3
−. With the exception of HA, sulfo groups can be found at
various O-positions in the sugar ring. KS, with a non-acidic
[-3Galβ1-4GlcNAcβ1]n backbone, is not listed.
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This review discusses progress over the last decade in pre-
paring free GAG chains using chemoenzymatic synthesis.
Enzymes, the best chemists on the planet, play a key role in
preparing these long and complex polymers in an efficient, reli-
able and greener fashion. Furthermore, this approach simplifies
the analysis of the products and provides a platform for gener-
ating oligosaccharide libraries.
Strategic planning and methodologies
Nature of the GAG targets
GAGs in the body range from tens to thousands of disacchar-
ide units in length depending on the tissue, age and health
conditions. The issue of chain-length polydispersity (the
breadth of the polymer size distribution) is important because
the physical nature [viscosity and occupancy of three-
dimensional (3D) space] as well as biological activities
(defined by the ability of proteins to bind) of GAGs change
depending on the size. The absence of sharply defined regula-
tion for polysaccharide size control in vivo has always been
an issue for the glycobiologist to grapple. In contrast, nucleic
acid and protein biosyntheses are template driven and utilize
origins/promoters and terminators or start and stop codons, re-
spectively, to afford defined macromolecular products.
In addition, for HS and CS, it is well established that the
sulfation pattern is very important for binding to target pro-
teins (Capila and Linhardt 2002; Lindahl and Li 2009).
Perhaps the most vexing and challenging issue is that sulfated
GAG biosynthesis in any cell-based system always results in
heterogeneous products. Multiple enzymes are operating in
the Golgi apparatus as the glycoconjugates translocate to the
cell surface; therefore, complete sulfation does not always
occur resulting in the biosynthesis of a variety of GAG
species. Is this observed GAG variety a complex code or a
result of cellular limitations? Or is there an inter-relationship
between these two possibilities that the human body has
exploited after 400–600 million years of evolution?
Chemoenzymatic synthesis of GAGs: attributes and hurdles
Chemoenzymatic syntheses and clever processing strategies
have now allowed the preparation of more defined GAGs and
GAG oligosaccharides as well as libraries of diversity and
purity greater than possible by extracting polysaccharides
from natural sources alone or by directed synthesis (Pervin
et al. 1995; Hileman et al. 1997; Yang et al. 2000; Liu et al.
2010; Xu et al. 2011; Chai et al. 2012). As described above,
large complex GAGs are not very amenable to current organic
synthesis methods; the repetitive steps of protection, activa-
tion, coupling and de-protection are quite laborious and often
require much optimization and customization for each step. In
addition, the control of product formation is less than ideal;
therefore, many separation steps may be needed to remove un-
desirable isomers (especially the incorrect anomers) as well as
the unavoidable failure products that add cost and decrease
overall yields. In contrast, enzymes have exquisite stereo-
selectivity (α- vs β-glycosidic linkages) and regio-selectivity
(position on sugar ring, e.g. C2, C3 etc.) for connecting
monosaccharide units. Most glycosyltransferases (GTases)
rarely appear to make a mistake with a natural substrate, but
by design enzymes can be “fooled” into using unnatural sub-
strates [see Uridine 5′-diphosphosphate (UDP)-sugar analogs
section].
Fortunately, many animal-derived and many microbial-
derived GAG polymerizing and modifying enzymes have been
identified, expressed and utilized for reactions in vitro
(Table II). The backbones of GAG chains can be efficiently
and controllably synthesized in vitro (as discussed in detail
later) using the relevant GTases to add the monosaccharide
units from UDP-sugar donors onto an acceptor or primer sugar
(Figure 1). The bifunctional GTases catalyzing GAG biosyn-
thesis are termed synthases (or polymerases) and are among
the most useful of enzymes for the synthesis of polysacchar-
ides in vitro.
One area that is still being elucidated is the control of the sul-
fotransferases (STases) that transfer sulfo groups from the donor
3′-phosphoadenosine-5′-phosphosulfate (PAPS) to the GAG
chain and the control of epimerases that convert GlcA into
IdoA. There are several types of N- and O-Stases (OSTs),
enzymes that add a sulfo group to the amine of a glucosamine
(GlcN) residue in HS or heparin or to a hydroxyl of a saccharide
residue, respectively. In many cases, there are multiple isozymes
with distinct substrate specificities within each STases class
(Esko and Selleck 2002; Pavão et al. 2006; Peterson et al. 2009;
Liu et al. 2012; Sheng et al. 2012). The OST isozymes exhibit
selectivity based on the sulfation state of the substrate. Basically,
putting on the first sulfo group on the GAG chain affects the ef-
ficiency and placement of subsequent sulfation added to the
same or proximal monosaccharide by other STases. For
example, 2-O-ST requires the prior introduction of an N-sulfo
group into the adjacent GlcN residue. Sulfatases may be
employed to remove certain sulfo groups as well.
The HS and chondroitin C5-epimerases (C5-epi; note two
distinct enzyme classes that only work on a single GAG type)
also exhibit complex specificity (Pacheco et al. 2009; Sheng
et al. 2012). The epimerization of HS, for example, requires
the presence of N-sulfo groups, and the rules for C5-epi acting
on CS epimerization are currently being elucidated (Sheng
et al. 2012). Therefore, if harnessed correctly and precisely,
many target GAG polymers are possible using chemoenzy-
matic synthesis.
Overview of chemoenzymatic GAG synthesis strategies
and challenges
The use of enzymes in vitro to produce or modify sugar poly-
mers by a variety of reactions (listed in Table II) has been
reported in a range of synthetic modes. As depicted in Figure 2,
these modes include: (a) a semi-synthetic approach where the
GAG backbone polymer produced in vivo is extracted from an
organism and then modified in vitro (reactions I–III, V–XII),
(b) swapping portions of existing GAG chains through transgly-
cosylation reactions in vitro (reaction VII), (c) building GAG
chains with degradation enzymes and transition state intermedi-
ates in vitro (reaction IV) or (d) building GAG chains with
synthases/GTases and UDP-sugars in vitro (reactions I–III, V,
VI). In all four formats, after sugar backbone isolation or syn-
thesis, modifications of the chain such as the addition/removal
of sulfo groups and/or isomerization of uronic acid moieties are
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pursued utilizing recombinant enzymes typically cloned from
vertebrates (reactions VIII and XI).
The semi-synthetic approach (a) employs naturally occurring
polydisperse polysaccharides; thus, there are cost savings on
purified UDP-sugars and enzymes, but the polymer size and
composition control are sacrificed (as well as the potential for
carryover of impurities). Typically, the GAG chain is isolated
either in a uniformly unmodified state from a microbial source
or in a complex heterogeneous state from an animal tissue
before treatment with various modification enzymes (see later
sections for examples). Domain swapping through transglyco-
sylation (b) may also use such “natural” GAGs as feedstocks.
When building GAGs with synthases/GTases and
UDP-sugars (Figure 1) (d) the GAG chain synthesis reaction
may be carried out in one of two preferred formats depending
on the target size: (i) step-wise elongation (i.e. one sugar unit
at a time) of oligosaccharides in vitro (reactions I–III; Figure 2,
mode D.2) or (ii) assembling a GAG polysaccharide in a syn-
chronized polymerization reaction in vitro (reactions V and VI;
Figure 2, mode D.3). Both of these formats yield more defined
products with narrow size distributions (monodisperse or
nearly so) and potentially more controllable compositions than
in semi-synthesis of a GAG polymer produced in vivo (a), in
domain swapping through transglycosylation (b) or in building
Table II. Useful GAG chemoenzymatic reactions
Reaction Catalyst examples
Oligosaccharide synthesis:
I. Acceptor + UDP-GlcA→GlcA-acceptor Mutant PmHAS or PmHS1 or PmHS2
II. Acceptor + UDP-HexNAc→HexNAc-acceptor Mutant PmHAS; KfiA
III. Acceptor + UDP-R analogs→R-acceptor PmHAS; PmHS2; KfiA
Polysaccharide synthesis:
IV. n R׳-oxazoline→GAGa Testicular hyaluronidase
V. Acceptor + UDP-GlcA + UDP-HexNAc→GAG-acceptorb PmHAS; PmHS1; PmCS; KfoC
VI. Acceptor + UDP-R + UDP-R”→GAG[R/R”]-acceptorb PmHAS; PmHS2; PmHS1/2 Chimeras
Chimeric GAG formation via transglycosylation:
VII. GAG1 + GAG2→GAG1-GAG2c Testicular hyaluronidase
Backbone modification:d
VIII. GAG→N-S-GAG GlcNAc N-deacetylase/N-STasee
IX. GAG(GlcA)→GAG(IdoA) Uronyl C5-epimerase
X. N-GAG→N,O-S-GAG OSTs
XI. N,O-S-GAG→N-S-GAG GAG sulfatases
Backbone transfer/activation:
XII. GAG-protein→GAG-R’” Patnopecten xylosidase
The general reaction schemes and examples of the relevant enzymes are summarized. See Figure 2 for a schematic overview. R’, R” = unnatural sugar analog;
R’” = another protein or alkyne.
aSee Figure 3 for details. In addition, more than one type of oxazoline intermediate can be co-polymerized to form hybrid GAGs.
bAn exogenous acceptor is not absolutely required for Vor VI because UDP-GlcNAc can serve as the initial acceptor (the resulting reducing terminal UDP on
the nascent GAG chain is labile). Also, chimeric HA/chondroitin GAGs can be made by this method as well depending on the choice of acceptor, donor and
synthase.
cNote that chain fragmentation of the donor GAG occurs to afford extension of the recipient acceptor GAG; only a simplified reaction overview is shown here
with the target chimeric GAG depicted.
dThe HS and CS modification enzymes do not cross-react with the non-cognate GAG (i.e. distinct STases, sulfatases and epimerases are required for each GAG
class).
eThis reaction can also be done chemically with the HS containing-GlcN[TFA] analog (reactions III or VI) via deprotection with base and chemical sulfonation.
Fig. 1. GAG elongation reactions. GTases, including the GAG synthases, can transfer an uronic acid (top) or a hexosamine (bottom) from a UDP-sugar donor to
an acceptor in vivo or in vitro. In this example, GlcA or GlcNAc, respectively, is transferred to a nascent heparosan chain.
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GAGs using degradation enzymes and transition state inter-
mediates (c). However, the use of synthases/GTases and
UDP-sugars (d) is considerably more expensive as it requires
purified components.
A further benefit of building GAGs using either degrad-
ation enzymes and transition state intermediates (c) or the use
of synthases/GTases and UDP-sugars (d) is that the monosac-
charide units in the GAGs produced may be either the natural-
ly occurring sugars or chemically synthesized unnatural
analogs possessing either new functionality (e.g. a tag or re-
active group) or a potential biological modifier moiety (i.e. a
group that prevents or enhances binding, signaling, cleavage
etc.) (reaction III or VI).
In any of these formats, a particularly useful strategy
(described in greater detail later) is to prepare a library of
similar modified GAGs in parallel where separate combinator-
ial syntheses each utilize an alternate order of addition or the
exact choice of the various GTases, STases, epimerase, sulfa-
tases etc. Each member of the library can then be tested for
bioactivities with proteins or in cultured cells or in animals and
also analyzed to define unique chemical structures responsible
for activity. Although the exact catalysts employed (down to
the specific isoforms) and the order of addition directs the syn-
thesis, precise control is not often possible when long polysac-
charides are subjected to modification reactions. Even if
overall disaccharide compositions are similar, their linear ar-
rangement can differ; the potential for various domain struc-
tures with different lengths, percentages of modified or
unmodified units or orientation (i.e. reducing vs non-reducing
terminus) adds another level of complexity to chemoenzymatic
synthesis.
After synthesis, it is also critical to verify the molecular
structure of the GAG product. However, it is currently beyond
analytical capabilities to establish the exact structure of intact
GAG chains larger than 5000 Da (equivalent to 20 sugars)
due to their complex physical–chemical properties and their
highly variable repeating disaccharide structure (Wang et al.
2010). In contrast, rapid, inexpensive and rather definitive
polypeptide or DNA sequencing is performed routinely; even
the sequencing of N-glycans is now possible in a number of
specialized laboratories. Typically, a GAG polymer must be
fragmented (using a bottom-up approach) to perform its disac-
charide compositional analysis and oligosaccharide mapping.
Recent top-down GAG sequencing methodologies relying on
tandem mass spectroscopy have been used to determine the se-
quence of intact GAG chains of short lengths (e.g. 25–43
monosaccharide units; Ly et al. 2011).
Production and use of natural structure and chimeric
backbones
Unsulfated GAGs, HA, chondroitin and heparosan (Table I),
can be prepared through microbial fermentation (DeAngelis
et al. 2002; Widner et al. 2005; Wang et al. 2010). This in
vivo approach using bacteria is currently limited to the pro-
duction of the natural GAG backbone, and furthermore, it is
difficult to prepare GAG backbones of defined molecular
weight. Production optimization, through genetic manipula-
tions or by varying fermentation conditions, has been
reviewed elsewhere (Cimini et al. 2012; DeAngelis 2012).
Several groups have focused on the native Escherichia coli
K5 heparosan as the HS/heparinoid starting material that is
then modified by various methods (described later in
“Modification”) as in reactions VIII-XI (Kuberan et al. 2003;
Li, Sheng, et al. 2012). Another interesting recent report for
preparing natural GAG backbones is the molecular cloning of
the E. coli heparosan production KfiA-D genes (encoding
three proteins of the GTase complex and the UDP-glucose de-
hydrogenase for making UDP-GlcA) into a laboratory strain
Fig. 2. Schematic of general GAG chemoenzymatic synthesis formats.
Various chemoenzymatic synthetic modes allow the enzymatic transformation
and/or production in vitro (arrows) of GAG oligosaccharides and
polysaccharides (black or white rectangles). In (A), a semi-synthetic approach
where the GAG backbone polymer produced in vivo is extracted from an
organism and then modified with enzymes (in this example, STase and
epimerase to add sulfo groups, S, and create IdoA, I) is employed. In (B),
testicular hyaluronidase swaps portions of existing GAG chains (donor, black,
and acceptor, white) through transglycosylation reactions to create a series of
related hybrid chains with extensions of different sizes in the population. In
(C), testicular hyaluronidase builds GAG chains by polymerizing oxazoline
disaccharides (box-oxa) to create a series of polymers with a wide size
distribution. In (D), GAG synthases/GTases transfer a single sugar or
thousands of sugars from UDP-sugar donors (box-UDP) depending on the
strategy employed. Three examples are shown here (from top to bottom):
(1) uncontrolled polymerization resulting in a series of products with a wide
size distribution, (2) single sugar extension of an acceptor (white rectangle) as
shown in Figure 1 or (3) acceptor-mediated synchronized extension to form
polymers with a narrow sized distribution (note: final product size is
controlled by acceptor/donor stoichiometry). These approaches can be
performed in series or combined or repetitively repeated to produce a wide
range of products, e.g. the GAG backbone products of B–D can be modified
as in A etc. For the specific reactions and useful catalysts, see Table II.
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of E. coli lacking the transporter proteins that are normally
employed to secrete capsular polymers. Therefore, these re-
combinant bacteria make the heparosan polymer intracellular-
ly (Barreteau et al. 2012). The same group also co-expressed
a heparosan-degrading enzyme (a lyase) in some constructs to
produce short oligosaccharides that would be a useful feed-
stock for the HS modification enzymes described later.
With respect to making natural GAG polymers in vitro,
much progress has been made using two entirely distinct
classes of carbohydrate-active enzyme tools. The first class,
the GTases (or various mutated versions), build GAGs through
the use of UDP-sugar precursors (Figures 1 and 2) that
emulate the cellular carbohydrate biosynthetic pathways. For
these methods, certain bacterial GTase enzymes have been
much more useful than the non-homologous vertebrate coun-
terparts due to better expression, higher stability and other in-
trinsic properties. Such catalytic workhorses include the
Pasteurella HA, chondroitin or heparosan synthases and their
homologs, and Escherichia KfiA [transfers α-N-acetylglucosa-
mine (α-GlcNAc) unit of heparosan; Table II] that have been
useful for making HA, chondroitin or heparosan polymers
(DeAngelis et al. 2003; Jing and DeAngelis 2004;
Sismey-Ragatz et al. 2007; Liu et al. 2010). These microbial
enzymes add sugars to the non-reducing terminus of acceptors
(Figure 1), the same directionality as the vertebrate enzymes.
The Streptococcus HA synthases, however, which operate
through reducing end addition (the opposite direction as
above), are not very useful catalysts in vitro due to their inabil-
ity to extend exogenously added sugar chains. Surprisingly, the
corresponding recombinant E. coli K5 GlcA-Tase enzyme,
KfiC, has not been useful as a catalyst in vitro due to expres-
sion problems when expressed independently of KfiA and B
(Sugiura et al. 2010).
The second class of useful catalysts is a natural HA and CS
degrading enzyme, testicular hyaluronidase (HAase; EC
3.2.1.35). This enzyme can be used in the “reverse” direction
to make polymers either by transglycosylation (a disaccharide
unit is added to the chain terminus rather than the hydrolysis of
the chain by a water molecule), swapping domains of existing
GAGs (Chen et al. 2009; Kakizaki et al. 2012; Table II, reac-
tion VII) or by the polymerization of disaccharide oxazoline
transition state intermediates (Ochiai et al. 2007; Figure 3;
Table II, reaction IV). Unfortunately, there is no known com-
parable enzyme with the ability to make heparosan or HS by
either of these approaches.
Domain swapping through transglycosylation has been used
to generate unnatural chimeric HA–CS or CS–HA GAGs,
where typically each reaction yields a series of oligosaccharide
products with very similar structures (i.e. not a specific tar-
geted product; reaction VII). Avariety of GAG polymers com-
posed of HA and/or chondroitin/CS have been reported (Endo
and Kakizaki 2012). DS, however, was not useful as an accept-
or or a donor GAG for transglycosylation; thus, the IdoA
appears to be blocking the reaction.
In a very useful example of using the HA degradation
enzyme and transition state intermediates to build GAGs
(Figure 3; Table II, reaction IV), 4-O-sulfo-N-acetylgalactosa-
mine (GalNAc) oxazoline intermediates were polymerized
with testicular HAase to produce a pure chondroitin-4-sulfate
(CS-A) polymer with molecular weights in the range of 104
(Fujikawa et al. 2005). Such a defined material is not found in
nature, particularly in common animal sources (e.g. shark,
bovine, porcine) where sulfo groups are present on a variable
fraction of the 2-, 4- and 6-O-positions within a given CS
chain. Unfortunately, the 6-O-sulfo GalNAc oxazoline cannot
currently be used produce the chondroitin-6-sulfate (CS-C)
polymer in a similar fashion. While chimeric HA–CS mole-
cules can be made by domain swapping through transglycosy-
lation (Figure 2B), or building GAGs using degradation
enzymes and transition state intermediates (c), the synthetic
control with respect to size distribution is not always possible.
These approaches do have the advantage of introducing
O-sulfo chondroitin in unique ways not yet possible using
synthases/GTases and UDP-sugars (d).
As examples of exquisite synthetic control utilizing GAG
GTases, two approaches using synthases/GTases and UDP-
sugars (d) have been employed to create either (i) defined oli-
gosaccharides (Table II, reactions I-III) or (ii) quasi-
monodisperse polysaccharides (reactions V and VI) (Figure 1).
For the goal of making long polymers (e.g. 10 to 3000
kDa) in a rapid fashion, the raw polymerizing ability of bifunc-
tional synthases, such as PmHAS, PmCS or PmHS1, is useful.
However, for shorter chains (i.e. oligosaccharides less than 20–
25 monosaccharide units), precise size control needs more
careful planning and/or the use of monofunctional GTases such
as synthase mutants or a naturally occurring enzyme such as
KfiA.
One strategy to harness the synthase for oligosaccharide syn-
thesis is to employ a pair of monofunctional synthase mutants
in an alternating stepwise fashion (e.g. reactions I then II and
so on; Figure 2, D.2) to elongate a GAG acceptor (DeAngelis
et al. 2003; Kane et al. 2006; Chavaroche et al. 2012).
Basically, Pasteurella synthases contain two relatively inde-
pendent GTases in one polypeptide chain; mutation of one
Fig. 3. Hyaluronidase-mediated GAG polymerization reaction. The creation of a GAG chain (HA in this example) by repetitive ligation of oxazoline
disaccharides by the HA-degrading enzyme is depicted. The cyclic oxazoline group mimics the transition state intermediate where the acetyl group participates in
the glycosidic bond cleavage during normal GAG degradation. Unsulfated HA or unsulfated chondroitin or 4-S chondroitin disaccharide intermediates, but not
6-S, may be employed in the “reverse” reaction to synthesize GAG polymers.
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active site (e.g. changing the critical DXD motif to NXN) typ-
ically does not affect the catalysis at the other site. A particu-
larly useful format is to immobilize the enzyme on a bead to
facilitate the removal of the catalyst after a step is finished,
because if both enzyme components, the GlcA-Tase and the
N-acetylhexosamine (HexNAc)-Tase, are present with both
types of UDP-sugars simultaneously, then runaway polymer-
ization will form undesirable longer products. HA chains up to
20 monosaccharides in length have been made by repetitive
extension of a tetrasaccharide acceptor using this stepwise ap-
proach (DeAngelis et al. 2003). This monofunctional mutant
method allows the reaction mixture to contain both
UDP-sugars and be continuously processed without GAG
intermediate purification steps after each sugar addition, a con-
siderable savings in both labor and time.
Alternatively, in a second oligosaccharide synthesis strategy,
any GAG GTase may be used for stepwise extensions
(Figure 1) with the following two provisos: only one
UDP-sugar (e.g. UDP-GlcA for reaction I) is added at a time
with the enzyme and each GAG oligosaccharide intermediate
is purified before proceeding to the next elongation step with
the second UDP-sugar (in this case, UDP-HexNAc for reaction
II) and the next GTase. Heparosan chains of up to 21 monosac-
charide units have been made using KfiA or PmHS2 (as the
source of GlcA-Tase) in alternating steps (Liu et al. 2010; Xu
et al. 2011, 2012). In a third strategy, the acceptor may be
immobilized on a surface [e.g. microplate well, nanoparticles
in a microfluidic channel etc. (Martin et al. 2009; Powell et al.
2010)] and the reaction mix containing a single GTase and a
single UDP-sugar that is exchanged at each step; this synthesis
method is ideally suited for the library or array format (Park
et al. 2008; Powell et al. 2010; Rogers and Hsieh-Wilson
2012).
Synchronized extension reactions (Table II, reactions V and
VI; Figure 2, D.3) have been employed with success to
produce nearly monodisperse size-defined polysaccharides
(chains greater than 20–25 monosaccharide units). Basically,
some non-processive GTase enzymes (e.g. PmHAS, PmCS
and PmHS1 synthases) elongate acceptors much faster than
they initiate new chains de novo. Therefore, in reactions with
acceptor, all the GAG chains are elongated in parallel; thus,
the extended polymers all possess very similar lengths or
quasi-monodisperse size distributions. In contrast, for reac-
tions without the acceptor (Figure 2, D.1), the new GAG
chain is formed through the coupling of the two UDP-sugars
in a slow process; the first such chains to be initiated will
have longer extension time compared with the various chains
started later in the reaction. Thus, such asynchronous exten-
sions yield polysaccharide products with a wide size distribu-
tion. The acceptor/donor ratio is varied to control the specific
size obtained. Polymers with polydispersities of 1.01–1.2
(close to the monodisperse value of 1) with sizes from 20
to 2000 kDa for HA (Jing and DeAngelis 2004) and 20 to
800 kDa for heparosan (Sismey-Ragatz et al. 2007) have
been obtained. In contrast, natural GAG polymers have much
higher polydispersities (1.3–2.5). With respect to scalability,
these synchronized reactions have been performed at the mul-
tigram level for commercial purposes (SelectHA™ of
Hyalose, LLC; HEPtune™ of Caisson Biotech, LLC).
As an example of a novel chimeric polymer made using
synthases/GTases and UDP-sugars (d), the Pasteurella HA
synthase will assemble block polymers of HA-unsulfated
chondroitin or HA–CS attached together; these structures
combine the two GAG components of aggrecan proteoglycan
assemblies without involving a core protein (Tracy et al.
2007). Similarly, the chondroitin synthases will make
chondroitin-HA or chondroitin-CS polymers. The basis for
these syntheses is that the two enzymes have discrete
UDP-sugar donor specificity, but they can extend non-cognate
GAG acceptors (i.e. either synthase can elongate HA or chon-
droitin acceptors as the HexNAc C4 position is not key for ac-
ceptor substrate recognition). The size of the extension is
controlled by stoichiometry of the GAG acceptor and the
UDP-sugars employed. As mentioned earlier, the alternative
method to create chimeric GAGs, transglycosylation (Table II,
reaction VII), is somewhat less controllable.
UDP-sugar analogs
Monosaccharides, in the form of UDP-sugar, are donors in the
polysaccharide biosynthetic pathway, being transferred to a gly-
cosyl acceptor by a GTase or a synthase (Watkins 1986). Natural
and unnatural GAGs can be prepared by using recombinant
GAG synthases and chemically modified UDP-sugar nucleo-
tides (reaction III or VI; Figure 1) (Sismey-Ragatz et al. 2007).
A major current, but fading, limitation to the enzymatic prepar-
ation of GAG polysaccharides and oligosaccharides is the avail-
ability and cost of sugar nucleotides and their analogs and
derivatives due to the difficulty of their syntheses (Karst and
Linhardt 2003). Although they can be prepared in several ways,
a purely chemical approach requires a long and tedious synthesis
and yields of UDP-donor are generally low and the production
of kilogram amounts is probably not commercially viable.
Chemical synthesis is particularly important in preparing unnat-
ural UDP-sugars such as UDP-IdoA (Weïwer et al. 2008).
Chemoenzymatic synthesis offers an alternative for the synthesis
of natural UDP-sugars and UDP-sugars containing some minor
modifications (Figure 4). Furthermore, chemoenzymatic synthe-
sis eliminates the use of protection and deprotection steps
required for chemical synthesis, circumventing the difficulties
inherent to the formation of a pyrophosphate bond.
Wang et al. reported the enzymatic synthesis of
UDP-GlcNAc/UDP-GalNAc analogs using recombinant E. coli
N-acetylglucosamine-1-phosphate uridyltransferase (GlmU;
Guan et al. 2009). However, low yields were reported for
N-modified GalNAc-1-phosphate analogs, a problem that was
later resolved using recombinant human UDP-GalNAc pyro-
phosphorylase (AGX1) for the synthesis of UDP-GalNAc
analogs (Guan et al. 2010). Chen et al. (2011) reported a
one-pot three-enzyme synthesis of UDP-GlcNAc derivatives
using a HexNAc-1-kinase and GlmU but only a few derivatives
were successfully synthesized (Figure 4). Alternatively, eight
different GalNAc-1-phosphate analogs have recently been
synthesized (Figure 4) and their recognition by the GlmU
enzyme has been studied (Masuko et al. 2012).
Out of the eight HexNAc-1-phosphate analogs tested, six
were accepted as substrates by GlmU, affording the correspond-
ing UDP-sugar nucleotides in high yields. GlmU accepted
neither 2-deoxy-2-azidoglucose (GlcN3)-1-phosphate nor
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GlcN-1-phosphate, so these two additional UDP-sugars
required chemical synthesis. GlcNAc-1-phosphate and N-tri-
fluoroacetylglucosamine (GlcN[TFA])-1-phosphate were excel-
lent substrates, yielding more than 70% conversion. Since
GalNAc-1-phosphate was accepted by GlmU, the 4-OH group
appears not to play a critical role in enzyme recognition. Both
GlcN-alkyne-1-phosphate and GalN-alkyne-1-phosphate gave
moderate yields of UDP-sugars using GlmU. Based on these
observations, it appears that the amide bond on the 2-amino
functional group is essential for substrate recognition by GlmU
but the configuration at C4 is not important.
However, even if one class of enzymes can make such
analogs, other catalysts such as the GTases are not assured of
having the same promiscuity. Therefore, these novel
UDP-sugar nucleotide analogs were then tested for incorpor-
ation by various GAG synthases in vitro. PmHAS and PmCS
produce HA and chondroitin polysaccharides, respectively
(Jing and DeAngelis 2003). PmHS1 and PmHS2 are two hom-
ologous isozymes that both can polymerize heparosan, the pre-
cursor of HS and heparin (Sismey-Ragatz et al. 2007). The
hexosamine analogs were tested in a chain polymerization
assay using radioactively labeled UDP-[3H]GlcA; a radioactive
signal results only if the hexosamine is co-polymerized into the
disaccharide repeats of a GAG product (Jing and DeAngelis
2000; Sismey-Ragatz et al. 2007; Masuko et al. 2012).
PmCS used both UDP-GalNAc and UDP-GalN-alkyne.
PmHAS utilized UDP-GlcNAc, UDP-GlcN-alkyne, UDP-GlcN
[TFA], UDP-GlcN-alkene and UDP-GlcN-N-tert-butoxycarbo-
nyl ([tBoc]). PmHS1 utilized UDP-GlcNAc, UDP-GlcN-
alkyne, UDP-GlcN-alkene and UDP-GlcN-[tBoc]. PmHS2 uti-
lized UDP-GlcNAc, UDP-GlcN-alkyne, UDP-GlcN[TFA],
UDP-GlcN-alkyne, UDP-GlcN-fluorenylmethyloxycarbonyl
([Fmoc]) and UDP-GlcN-[tBoc] (Masuko et al. 2012).
Unfortunately, neither PmHS1 nor PmHS2 nor PmCS accepted
UDP-IdoA as a donor (Weïwer et al. 2008); thus, the C5-epi
will continue to be needed to make natural HS or DS GAGs.
Production of GAG analog backbones
Two approaches have been utilized to prepare novel polymers
with unnatural structures unlike animal-derived GAGs: the use
of known GAG GTases with UDP-sugar analogs that substitute
for a natural sugar unit (Table II, reactions III and VI), and
novel synthases that polymerize non-animal GAG structures. In
the first case, sugar analogs (discussed in the previous section)
have been tested that (i) increase the hydrophobicity of the
normal HexNAc unit (e.g. GlcN-propanoyl or GlcN-butanoyl
with one or two extra CH2 groups, respectively), (ii) add a new
chemical functionality (e.g. 6-azido-GlcNAc, GlcN-propyne
etc.) or (iii) allow selective deprotection to reveal a new func-
tionality (e.g. GlcN[TFA] to GlcN using base treatment). In
summary, some synthases can use certain UDP-sugar analogs
as both a donor (to add onto a growing chain) and an acceptor
(to serve as a site for extension). Surprisingly, reagents with
substitutions at the 6-OH or the 2-N positions of the HexNAc
can be accommodated by multiple GTase enzymes.
A particularly interesting case is the UDP-GlcN[TFA]
analog; the Pasteurella PmHAS, PmHS2 and the E. coli KfiA
can utilize this analog quite well. The TFA protecting group
can be removed selectively by mild volatile base treatment,
without removal of any natural acetyl groups or cleavage of
the GAG chain. The new amine in a GAG chain is useful for
attaching amine-reactive molecules (e.g. NHS-esters, isothio-
cyanates) or for N-sulfonation by either an enzyme (reaction
VIII) or a simple chemical reagent. Therefore, the careful
placement of a GlcN[TFA] unit in an oligosaccharide using
reaction III (Liu et al. 2010) or a polysaccharide by reaction
VI (Sismey-Ragatz et al. 2007; Otto et al. 2012) will direct
selective N-sulfo modification. In the case of HS biosynthesis,
the introduction of an N-sulfo group is the first step of heparo-
san modification, thus allowing the glycochemist to emulate
nature.
A technical issue on this front, however, is that the native
enzymes are sometimes not ideal. Specifically, PmHS2 uses
the TFA analog quite well, but this enzyme does not make
monodisperse polymers and is prone to starting chains de
novo rather than building exclusively on existing chains. In
contrast, PmHS1 does not use the TFA analog with high effi-
ciency, but makes narrow size distribution heparosan chains
and prefers to elongate existing chains. Therefore, a panel of
PmHS1/PmHS2 chimeric enzymes was generated and
screened for both analog use and acceptor elongation activity
(Otto et al. 2012). A new catalyst with the combination of
useful attributes from both synthases was shown to be useful
in forming heparosan with defined blocks or segments of
GlcA-GlcNAc and GlcA-GlcN[TFA] repeats. Goals for such
synthetic HS precursors include determining how the initial
N-sulfate domain controls/influences the pattern of epimeriza-
tion and/or the introduction of O-sulfo groups.
Fig. 4. Enzymatic synthesis of UDP-GlcNAc and UDP-GalNAc analogs. A variety of UDP-sugar precursor analogs can be produced. Two alternative strategies
are employed to create the 1-phosphorylated monosaccharide: chemical synthesis (Masuko et al. 2012; italics) or enzymatic synthesis (Chen et al. 2011; bold;
NahK =N-acetylhexosamine 1-kinase). Then UDP is exchanged for the phosphate by GlmU to create the UDP-sugar. PpA (pyrophosphatase) drives the reaction
by cleaving pyrophosphate, PPi, to inorganic phosphate, Pi. Donor analogs are then useful substrates for production of the GAG chain by synthases or GTases.
The new functional group, R, can alter the GAG’s chemical reactivity, biological response and/or chemophysical properties. In addition to the C2 position of the
HexNAc (shown here), C6 has been relatively amenable to modification.
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In a separate pursuit to expand the GAG toolbox, bioinfor-
matic screens for homologs/analogs of known synthases seeks
to find catalysts with alternative transferase activities. A novel
GAG producing enzyme, CtTS, was identified that produces
the heparosan analog, testosteronan (Otto et al. 2011). This
new polymer has α-linked rather than the β-linked GlcA
found in heparosan (Figure 5). Some HS-binding proteins
may tolerate the testosteronan backbone, whereas others will
not; therefore, alternative selectivity may be observed due to
its alternative glycosidic conformation.
Modification of GAG backbones with STases, epimerases
and sulfatases
The biosynthesis of heparin and HS in animals is achieved by
a similar group of enzymes, while certain specialized enzymes
might be required for the complete biosynthesis of heparin.
The pathway involves multiple enzymes, including HS poly-
merase, epimerase and STases (Figure 6). The pathway covers
the synthesis of a linkage region tetrasaccharide, backbone
elongation and backbone modification. In some cases, sulfa-
tases then remodel the HS chain by removing certain O-sulfo
groups. Although CS chains are started similarly with the same
linkage tetrasaccharide, the biosynthetic pathways then diverge
using distinct elongation and modification enzymes.
In nature, the sulfated GAGs assemble while attached to a
core protein of a proteoglycan via a linkage region
(GlcA-Gal-Gal-Xyl), which requires four enzymes for its as-
sembly. The first GlcNAc is added by EXTL3, then the HS
polymerase (EXT complexes) adds alternating GlcA and
GlcNAc units generating an unsulfated and unepimerized HS
backbone. The backbone is then modified by N-deacetylase/
N-STase, C5-epi (converting GlcA to IdoA), 2-OST, 6-OST and
3-OST to produce the fully modified HS. In contrast, CS is
initiated by adding a β-linked GalNAc to the linkage tetrasac-
charide followed by elongation with the unsulfated
GlcA-GalNAc backbone via chondroitin polymerases (not
homologous to EXTs nor bacterial synthases). The chain is
modified by various chondroitin-specific STases (4-, 6- and/or
4,6-OSTs) depending on the tissue and developmental state. To
create DS, two C5-epi enzymes (distinct from the HS-acting
enzyme) convert elected GlcA residues to IdoA residues to
afford DS.
An abundant source of enzymes for carrying out the che-
moenzymatic modification of HS and heparin are recombinant
vertebrate proteins expressed in E. coli, insect cells and yeast
(Figure 6). The use of Kluyveromyces yeast to make key modi-
fication enzymes in readily purified, secreted soluble forms
facilitates what was once a laborious process (Zhou et al.
2011). In the same report, a method to prepare PAPS, the sulfo
donor that all STases require, in a much more economical
fashion (1/5000 of previous costs) was described. These
HS-active enzymes are currently used to modify the polysac-
charides and oligosaccharides in vitro to synthesize products
with different sulfation patterns. The applied use of the compar-
able recombinant CS-active enzymes has recently been used to
make a variety of 4-, 6- or 4,6-O-sulfo-chondroitin chains from
an unsulfated backbone made with the E. coli K4 chondroitin
polymerase (Sugiura et al. 2012).
Defined heptasaccharide analogs of Arixtra®, the synthetic
drug prepared laboriously using organic chemistry, were pre-
pared by stepwise chemoenzymatic synthesis by Table II,
Reactions I–III (Figure 2, D.2) followed by reactions VIII–X
(Xu et al. 2011). First, a disaccharide acceptor was extended
stepwise by incubation with KfiA and a UDP-hexosamine
(either UDP-GlcNAc or UDP-GlcN[TFA]) then by PmHS2
and UDP-GlcA; the process was repeated to make the GAG
backbone. Strategic positioning of the TFA-containing units
directed the precise installation of the N-sulfo groups after
basic deprotection and N-STase treatment. The oligosacchar-
ides were treated either during or after completion of the back-
bone synthesis process with epimerase and OSTs (order of
addition 2-, 6-, 3-OST). These 10- or 12-step processes gave
45 or 37% yields, respectively, and the products possessed
very similar anticoagulant potencies to Arixtra®.
Another superb example by the same group was the che-
moenzymatic synthesis of oligosaccharides up to 21-mers
containing the binding sites for both antithrombin III (AT)
and thrombin separated by a short linker (Xu et al. 2012).
While not structurally homogenous, due to the incomplete
action of the GAG modification enzymes, C5-epi and 2-OST,
the 21-mer product had the desirable anticoagulant activity.
Another recent advance was reported where the anticoagu-
lant properties of naturally occurring heparin were improved
through remodeling with recombinant human sulfatase (Sulf2)
to remove specific 6-O-sulfo groups (Table II, reaction XI)
Fig. 5. Comparison of unmodified heparosan, epimerized heparosan and
testosteronan (top to bottom). The differences in the structures of the various
GAG polymers may allow for recognition by certain HS-binding proteins, but
not others, thus opening possibilities for discovery of more selective ligands.
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involved in platelet factor 4 binding, which did not affect
binding of antithrombin III (Pempe et al. 2012). This modifi-
cation should reduce the detrimental side effect of
heparin-induced thrombocytopenia. Another promising target
area is non-anticoagulant heparins; basically, animal-derived
heparin has many activities with potential for use in cancer
and inflammation, but these leads cannot be fully exploited
because of bleeding complications that would be associated
with most current preparations. Thus, while semi-synthetic
methodologies (a) may be useful for a safer and more con-
trolled supply chain, in the long term, building GAG chains
with synthases/GTases and UDP-sugars (d) may provide the
safest products.
Synthesis of neoproteoglycans
In further steps toward the synthesis of artificial glycoconju-
gates, methods have been reported with utility to construct pro-
teoglycan mimics by attaching natural GAG chains to other
macromolecules. One interesting example of the semi-synthetic
approach involves isolating then functionalizing a CS chain
from a proteoglycan through a transglycosylation reaction
(Table II, reaction XII; Yamaguchi et al. 2010). Basically, the
Patnopecten endo-β-xylosidase cuts the GAG chain at the
linker tetrasaccharide, but when cleaving in the presence of
propargyl alcohol (containing a alkyne functionality), this
reagent is added to the reducing end of the CS chain instead of
a water molecule. The released GAG is suitable for “click”
chemistry with azido groups present on another molecule.
The same group in another report described employing trans-
glycosylation with the same xylosidase to reconstruct
neoglycoproteins; the GAG chain was added to a suitable ac-
ceptor peptide lacking a GAG chain (Endo and Kakizaki
2012). The same report also described the use of a trimmed
decorin proteoglycan as the acceptor for adding on new GAG
chains with HAase using transglycosylation (Figure 2B;
Table II, reaction VII). Although it is difficult to control pre-
cisely the GAG portions of these novel products, such strides
are promising first steps for re-creating or re-modeling proteo-
glycans to assess the biological roles of both the GAG and the
core protein molecules.
Production of GAG libraries
Since the first carbohydrate microarray appeared in the literature
in 2002 (Wang et al. 2002), such microarrays have been prom-
ising tools to probe carbohydrate–protein interactions, particu-
larly in the developing field of glycomics (Wang 2003; Noti
et al. 2006; Stevens et al. 2006; Ban and Mrksich 2008; Liang
et al. 2008; Park et al. 2008). Over a thousand spots on a
microarray chip can be conveniently monitored using very
small amounts of both ligand and analyte to elucidate the spe-
cific antibodies useful in the diagnosis of diseases, to identify
inhibitors of carbohydrate–protein interactions and to study
events involving carbohydrate–cellular interactions (Feizi
et al. 2003; Flitsch and Ulijn 2003; Wang 2003; de Paz, Noti,
et al. 2006; de Paz and Seeberger, 2006; de Paz, Spillmann,
et al. 2006;Noti et al. 2006; Stevens et al. 2006; Zhi et al.
2006; de Paz et al. 2007; Ban and Mrksich 2008; Liang et al.
2008). Despite the importance of measuring binding events
on carbohydrate microarrays, this technology has not been ex-
tensively applied to probe protein binding to GAGs because
Fig. 6. The biosynthetic pathway of HS. To maintain clarity, the steps involved in the synthesis of the backbone have been excluded. The modifications require a
series of specialized enzymes, including N-deacetylase/N-STase, C5-epimerase, 2-OST, 6-OST and 3-OST. The modification sites at each step are boxed. All of
these transformations have been reproduced in vitro via chemoenzymatic synthesis.
GAG chemoenzymatic synthesis
773
of their heterogeneity. 2D surface chemistries for site-specific
and covalent immobilization generally result in low signal in-
tensity and substantial non-specific binding of target proteins
because of an insufficient number of binding sites and the
presence of surface-protein interactions. Chip design using
polymers such as hydrogels or dendrimers provide a 3D struc-
ture with more binding sites required for signal amplification
(Seurynck-Servoss et al. 2007). Specific interactions between
heparin and AT were observed on a poly-L-lysine-based 3D
HepGlyChip providing enhanced signal to noise ratio and
minimized non-specific binding of AT (Park et al. 2008).
Microfluidics and lab-on-a-chip technologies enable reac-
tions on the micro scale and the nano scale, reducing reagent
consumption and analysis time, increasing reaction control and
throughput, and providing opportunities for full automation
(Srinivasan et al. 2004). Two types of microfluidic systems
have been developed: (i) channel microfluidics, which involves
fluid flow in patterned channels; and (ii) digital microfluidics,
wherein open droplet movement occurs through the process of
electrowetting on a 2D grid-like platform. Digital microfluidics
has gained popularity by eliminating many of the constraints
associated with fixed channels (Wheeler 2008) and allowing in-
dividual droplets in a biochemical array to be addressed. Some
previous applications of digital microfluidics include glucose
and other enzyme-based assays, preparation of protein samples
for matrix-assisted laser desorption/ionization mass spectrom-
etry, polymerase chain reaction and cell-based assays
(Srinivasan et al. 2004; Chang et al. 2006; Moon et al. 2006;
Barbulovic-Nad et al. 2008; Miller and Wheeler 2008; Kwon
et al. 2012).
Digital microfluidics chips consist of an array of electrodes
coated with an insulator followed by a hydrophobic layer
(Figure 7). Droplet movement in digital microfluidics is driven
by electrowetting, the ability of a surface to tune its wettability
by the application of electrical pulses. To operate a digital
microfluidic device, a droplet of fluid is placed over one elec-
trode and then a voltage is applied to an adjacent electrode,
causing the insulator above that electrode to become charged.
This process makes the destination electrode more hydrophilic
causing the droplet to move (Wheeler 2008). This wettability
of the surface is reversible, thus allowing the droplet to be
moved to an adjacent electrode of choice. In this manner,
sample-containing droplets may be transported, mixed and
separated on the chip.
HS was modified by 3-OST-1 using digital microfluidics to
afford an HS with an increased affinity for the anticoagulant
protein AT (Martin et al. 2009). This research represents a
first step towards the construction of an artificial Golgi organ-
elle that may serve as a test-bed to better understand how the
natural Golgi controls the biosynthesis of GAGs.
Summary and future directions
In the last decade, various groups have made great strides in
producing GAGs with structures identical or similar to natural
molecules in vitro. With respect to molecular weight control
of the GAG backbone, scientists have bested the natural pro-
ducts as demonstrated by the creation of nearly monodisperse
artificial preparations. For HS, the positioning of N-sulfo
groups can be done very precisely within a GAG chain in
vitro. But the lack of precise control in introducing O-sulfo
groups and epimerizing uronic acid residues in vitro can still
humble scientists trying to prepare lab-made GAGs. Despite
these challenges, some artificial GAGs are still more defined
than the heterogeneous GAGs extracted from animal sources.
Perhaps microfluidic-based syntheses will allow further refine-
ment of chemoenzymatic methods and result in higher effi-
ciencies and/or better control of sequential backbone
modifications.
The forthcoming availability of defined GAGs promises to
help both basic and applied science in making discoveries
towards structure/function relationships of GAGs. The avail-
ability of synthetic GAGs should help sort out the role of sul-
fated domain structures in fine-tuning the biological outputs.
Fig. 7. Digital microfluidic chip used to perform enzymatic reactions. The top
panel is a magnified picture of a digital microfluidic chip of gold electrodes,
buffer reservoirs and wires on a glass substrate coated with Teflon. A glass
coverslip coated with a transparent and conductive layer coated with a thin
layer of Teflon is laid on top of a spacer on this digital microfluidic chip
(bottom panel). The gap between the digital microfluidic chip electrode and
the glass coverslip is filled with internal silicone oil (this serves to minimize
the evaporation of these nanoliter-sized droplets. Samples in aqueous buffer
containing Golgi enzymes, UDP-sugars and PAPS are placed on buffer
reservoirs through holes in the coverslip and are held in position by applying
a voltage to the reservoirs through a connecting wire (Martin et al. 2009).
When a voltage is applied to a buffer reservoir or electrode-square the
hydrophobicity of the Teflon layer is overcome through electrowetting making
the aqueous droplet adhere to the newly hydrophilic surface. Droplets can be
split off from the reservoir droplet and moved to the adjacent electrode-square
by applying voltages. Once the droplet is transferred to an electrode it can be
similarly moved to the adjacent electrode, merged with another droplet or
split into two droplets on separate electrode-squares. Thus, enzymes can be
added to substrates and reactions can be conducted with both temporal and
spatial control.
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The availability of such designer GAGs, produced in vitro,
promises more consistent and selective new therapeutic pro-
ducts and a better-secured supply chain. We look forward to
the next decade of new developments in synthetic control to
improve scale-up, allowing broader exploration and access of
these critically important biopolymers.
In the distant future, metabolic engineering may be used to
construct GAGs in cultured animal or microbial cells, allow-
ing a single cell line to produce the products with desired
structures. The production of GAGs using a metabolic engin-
eering approach is no easy task. Even seemingly simple ma-
nipulation, such as switching the production of HS to heparin
in cultured Chinese hamster ovary (CHO) cells, poses an in-
credible challenge (Baik et al. 2012). For example, the overex-
pression of NDST-2 and 3-OST-1 in CHO cells cannot yet
yield polysaccharides that resemble heparin, suggesting gaps
in our fundamental understanding of control in GAG biosyn-
thesis. Yeast cells, also containing a Golgi, have been engi-
neered to prepare humanized glycoproteins (Wildt and
Gerngross 2005). Ultimately, it might even be possible to en-
gineer sulfated GAGs in bacteria (Wang et al. 2011). Despite
those challenges, a cleverly designed metabolic engineering
approach might one day provide a unique solution to simplify
the multi-enzyme synthesis of GAGs.
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transferase; Tase, transferase; [tBoc], N-tert-butoxycarbonyl;
[TFA], trifluoroacetyl; UDP, uridine 5′-diphosphosphate.
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